Clinical trials
Low Grade Serous Ovarian Cancer clinical trials
Below are recruiting low grade serous ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 74 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05113368RecruitingPhase 2
Regorafenib plus fulvestrant for recurrent low-grade ovarian cancer
This trial tests whether regorafenib (a targeted pill) plus fulvestrant (an injection that lowers estrogen signaling) can slow down recurrent low-grade serous ovarian cancer. It may help people whose cancer has returned after prior treatments.
Cleveland, OhioAges 18 years+ - NCT06547840RecruitingPhase 1
Study of MOv18 IgE for ovarian, endometrial, and breast cancers with a specific marker
This trial tests a new antibody treatment called MOv18 IgE for patients with advanced ovarian, endometrial, or triple-negative breast cancers that have a protein called folate receptor alpha (FRα) on their tumor cells. The goal is to see if the treatment is safe and effective.
BristolAges 18 years+ - NCT06394804RecruitingPhase 2
Avutometinib, Defactinib, and Letrozole for Low-Grade Ovarian Cancer
This trial tests a combination of two oral targeted drugs (avutometinib and defactinib) plus letrozole (a hormone therapy) in people with low-grade serous ovarian cancer who have not yet had any systemic treatment.
Atlanta, GeorgiaAges 18 years+ - NCT04111978RecruitingPhase 3
Maintenance hormone therapy after ovarian cancer responds
This Phase 3 trial tests whether ongoing treatment with an aromatase inhibitor (a hormone-blocking medicine) after initial chemotherapy can help keep epithelial ovarian/fallopian tube/peritoneal cancer from coming back. It is only for certain tumor types that are hormone-receptor positive (ER+).
GrazAges 18 years+ - NCT06180356RecruitingPhase 2
Niraparib after surgery for ovarian cancer with limited spread
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
A CoruñaAges 18 years+ - NCT05512208RecruitingPhase 2
Avutometinib plus defactinib for RAS or BRAF mutated gynecologic cancer
This Phase 2 trial tests a two-drug treatment (avutometinib plus defactinib) for certain advanced gynecologic cancers that have specific cancer-driving DNA changes (like RAS or BRAF). It’s designed for people whose cancer has returned or gotten worse after at least one prior treatment for metastatic disease.
Orlando, FloridaAges 18–99 - NCT06072781RecruitingPhase 3
Study of Avutometinib + Defactinib for recurrent low-grade ovarian cancer
This trial tests a combination of two oral targeted drugs for people with recurrent low-grade serous ovarian cancer. It aims to see if this therapy works better than standard hormone therapy or chemotherapy options.
Phoenix, ArizonaAges 18 years+ - NCT05773859RecruitingPhase 1/Phase 2
Vaccination before surgery to treat advanced ovarian cancer
This trial studies a vaccine made from your immune cells (dendritic cell vaccine) given before chemotherapy and surgery. It aims to help your body recognize and fight ovarian cancer more effectively in people whose cancer is advanced and spread.
Nijmegen, GelderlandAges 18 years+ - NCT05950464RecruitingPhase 1
Dose study of two targeted drugs for recurrent ovarian cancer
This Phase 1 trial tests different doses of two study drugs (M1774 and ZEN-3694) for recurrent ovarian cancer and some recurrent endometrial cancers. It aims to find a safe dose and see how well the treatment works, especially in cancers with certain tumor features.
Augusta, GeorgiaAges 18 years+ - NCT05872204RecruitingPhase 2
Abemaciclib plus letrozole for rare ER-positive ovarian cancer
This trial tests whether abemaciclib with letrozole can slow or shrink certain rare ovarian cancers that have estrogen receptors. It may help people whose cancer has come back and can be measured on scans, with extra required tissue and blood tests.
Liège, LiègeAges 18 years+ - NCT05659381RecruitingPhase 3
Heated belly chemo plus niraparib after interval surgery for ovarian cancer
This Phase 3 study tests whether heated chemotherapy placed inside the belly, followed by interval surgery and the maintenance medicine niraparib, can improve outcomes for certain advanced ovarian, fallopian tube, or primary peritoneal cancers. It focuses on people whose tumors are HRD/LOH positive and who can have all visible disease removed.
Duarte, CaliforniaAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT05316129RecruitingPhase 1
Trial of your own engineered T cells for ovarian cancer
This Phase 1 study tests whether giving your own immune cells—engineered to target the FSH receptor—can control recurrent ovarian-related cancers. It’s mainly looking at safety and early signs of activity for patients whose cancer has not responded well to standard platinum chemotherapy.
Tampa, FloridaAges 18 years+ - NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Mobile, AlabamaAges 18 years+ - NCT05231122RecruitingPhase 2
Pembrolizumab and bevacizumab for recurrent ovarian cancer
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Buffalo, New YorkAges 18 years+ - NCT05183984RecruitingPhase 2
Niraparib plus bevacizumab after complete ovarian cancer surgery
This trial tests whether niraparib, taken after surgery, works better when combined with bevacizumab in people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have no visible tumor left. It also aims to see if this approach helps prevent the cancer from coming back.
AngersAges 18–99 - NCT05128825RecruitingPhase 2
Azenosertib for platinum-resistant ovarian cancer with cyclin e1
This trial tests a new pill called azenosertib (ZN-c3) for ovarian cancer that stopped responding to platinum chemotherapy. The drug targets tumors with high levels of the Cyclin E1 protein, and the goal is to see if it can shrink tumors or slow the cancer's growth.
Mobile, AlabamaAges 18 years+ - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT04918186RecruitingPhase 2
Immunotherapy for platinum-resistant ovarian, with tumor testing
This Phase 2 study tests an immunotherapy approach for women whose high-grade serous ovarian cancer came back within 6 months of platinum chemotherapy. It may help shrink tumors and improve control of the disease, but you’ll need tumor biopsies and lab/heart/lung checks to join.
Chicago, IllinoisAges 18 years+ - NCT03564340RecruitingPhase 1/Phase 2
Testing ubamatamab alone or with cemiplimab for ovarian and MUC16+ cancers
This early-phase study tests ubamatamab, a cancer-targeting antibody, given by itself or with cemiplimab. It is meant to treat adults whose cancer has come back and who may not have other good standard options left.
Birmingham, AlabamaAges 18 years+ - NCT00488878Recruiting
Collecting information for certain low-grade ovarian or peritoneal tumors
This study collects health information from people whose ovarian or peritoneal cancer started as a low-grade type but later changed to a higher-grade cancer. It may help researchers better understand how these tumors progress and what to expect over time.
Houston, TexasAges Any age - NCT06404671Recruiting
Timing of surgery after chemo for advanced ovarian cancer
This trial tests whether waiting longer between chemotherapy and surgery affects outcomes for advanced ovarian cancer. It is for women who have had three cycles of chemo and whose disease can be removed surgically.
AlexandriaAges 18–75 - NCT06560112RecruitingPhase 2
Combination therapy trial for recurrent ovarian cancer
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
ShanghaiAges 18 years+ - NCT05610735RecruitingPhase 1/Phase 2
Study drug combination for ovarian cancer after platinum stops working
This Phase 1/2 trial tests a combination treatment for recurrent ovarian, fallopian tube, or primary peritoneal cancer when platinum chemotherapy stops working. If you qualify, the study aims to control the cancer and see how well the treatment is tolerated.
Louisville, KentuckyAges 18 years+
Hear when a new Low Grade Serous Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for low grade serous ovarian cancer?
- Yes. Clin2 currently lists 74 recruiting low grade serous ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a low grade serous ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a low grade serous ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.